Cyclerion Therapeutics Inc (CYCN) Stock Price, Quote & News

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8778

Website: www.cyclerion.com

Address:

245 First Street, Riverview II, 18th Floor, Cambridge, United States

StockTwitsGhost Mar. 21 at 1:31 PM

$CYCN 🦜 missed this 7 months ago. The scientific connection between Cyclerion, Karolinska, and Dr. John Pernow predates CVCO/Epizon’s involvement by years. A 2023 publication in JACC: Basic to Translational Science by Pernow’s group at Karolinska — studying sGC stimulation in red blood cells in type 2 diabetes patients — lists G. Todd Milne as a co-author alongside Pernow and his Karolinska colleagues, while also acknowledging Cyclerion scientists Emmanuel Buys, Jennifer Chickering, and Michelle Hewitt for their contributions. Milne, notably, is COO of Tisento Therapeutics. The Tisento/Cyclerion/Karolinska scientific relationship was therefore already firmly established before CVCO entered the picture. https://www.jacc.org/doi/10.1016/j.jacbts.2023.02.017

1 · Reply

AshleySchaeffer_BMW Mar. 20 at 8:10 PM

$CYCN which one of you full clipped a 30k buy at close today lol?

1 · Reply

skyrockets_Inc Mar. 20 at 8:08 PM

$CYCN @Bullbear1010101 what happened to your daily price updates? 1.58 now

2 · Reply

EZYME22 Mar. 20 at 7:43 PM

$CYCN has the epizon pharma website always been active @StockTwitsGhost ?

1 · Reply

EZYME22 Mar. 19 at 8:04 PM

$CYCN the partial first close if insider heavy and depending on structure could definitely make the audit fair value assessment and disclosure less straight forward or clean

2 · Reply

StockTwitsGhost Mar. 19 at 7:24 PM

$CYCN The reconciled records confirm that 9,199,985 PWP preferred shares are already issued and outstanding as of December 31, 2025, and shares do not become issued and outstanding without someone paying for them. That is not an empty authorization waiting for investors. That is a completed transaction. The remaining approximately 8.6 million authorized but unissued PWP shares represent capacity that is standard in institutional biotech financings, built in deliberately for additional tranches, pro rata participation by existing investors, or strategic investors who may come in after topline data. This structure fits the Tisento situation remarkably well. A first close in late 2025 funds operations through the PRIZM topline data readout expected Q4 2026, with the remaining authorized capacity held deliberately for a larger and more strategically timed announcement tied to that clinical milestone. That would explain precisely why there has been no press release from Tisento.

2 · Reply

StockTwitsGhost Mar. 19 at 7:05 PM

$CYCN Delaware Secretary of State records pulled today confirm a certificate of amendment filed by Tisento Therapeutics Holdings Inc. on December 4, 2025. The full amendment document is being retrieved and will be available shortly. For those following Cyclerion, the significance of this date cannot be overstated.

2 · Reply

StockTwitsGhost Mar. 19 at 6:52 PM

$CYCN The Delaware Secretary of State records show a certificate of amendment filed by Tisento Therapeutics Holdings Inc. File Number 7090306 on December 4, 2025 and this single data point is significant. December 4 is 27 days before year end. You do not file a certificate of amendment eliminating an entire share class in Delaware unless investor negotiations are complete, terms are signed, and counsel has been instructed to prepare the legal structure for closing. This is the second to last step in a private preferred financing. Funding is the last step. That places the Series B closing somewhere in the narrow window between December 4 and whenever the final wire cleared, which is either before December 31 landing directly on the FY2025 balance sheet, or just after making it a subsequent event footnote. Either way the gap is weeks not months. What makes this find particularly valuable is that Delaware certificates of amendment for preferred financings almost always contain…

2 · Reply

skyrockets_Inc Mar. 19 at 2:14 PM

$CYCN If the 10K gets delayed then it's most certainly tied to the Tisento Series B, which will be a major catalyst for the stock. Clearly been consistent loading for the last 1.5 month straight. The market always knows....I'm loaded up and can't wait.

2 · Reply

StockTwitsGhost Mar. 18 at 9:43 PM

$CYCN Larry 🦜2.0 just had this to say The most realistic assessment for the 10-K is a coordinated strategic hold caused by the immense audit complexity of revaluing the Tisento stake. Because Cyclerion’s potential $20M+ gain is tied to a private entity, auditors (EY) require exhaustive verification of the new "Fair Value" (ASC820) before signing off, a process that often hits a bottleneck in the final weeks of March. Management is likely bypassing the Massachusetts state filing and delaying an SEC extension (NT 10-K) to avoid signaling a "failure" to the market, instead fighting to finalize the 10-K by the March 31 deadline. Ultimately, the silence suggests an active negotiation to capture a massive balance sheet win rather than an operational collapse, as the company’s recent high-level advisory appointments and the Tisento state-level share restructuring point toward a value-unlocking event that is simply difficult to quantify on paper.

1 · Reply

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Jan 5, 2026, 4:01 PM EST - 2 months ago

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Sep 23, 2025, 4:01 PM EDT - 6 months ago

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Dec 17, 2024, 8:08 AM EST - 1 year ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 2 years ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 3 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 3 years ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 3 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 3 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 3 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 4 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 4 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 11:27 AM EDT - 4 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Oct 20, 2021, 4:24 PM EDT - 4 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 5 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 9, 2021, 6:14 AM EDT - 5 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 8, 2021, 7:22 PM EDT - 5 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 10:27 AM EDT - 5 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 12:03 PM EDT - 5 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Apr 27, 2021, 9:00 AM EDT - 5 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 26, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Apr 21, 2021, 7:30 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Apr 20, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar

StockTwitsGhost Mar. 21 at 1:31 PM

1 · Reply

AshleySchaeffer_BMW Mar. 20 at 8:10 PM

$CYCN which one of you full clipped a 30k buy at close today lol?

1 · Reply

skyrockets_Inc Mar. 20 at 8:08 PM

$CYCN @Bullbear1010101 what happened to your daily price updates? 1.58 now

2 · Reply

EZYME22 Mar. 20 at 7:43 PM

$CYCN has the epizon pharma website always been active @StockTwitsGhost ?

1 · Reply

EZYME22 Mar. 19 at 8:04 PM

$CYCN the partial first close if insider heavy and depending on structure could definitely make the audit fair value assessment and disclosure less straight forward or clean

2 · Reply

StockTwitsGhost Mar. 19 at 7:24 PM

2 · Reply

StockTwitsGhost Mar. 19 at 7:05 PM

2 · Reply

StockTwitsGhost Mar. 19 at 6:52 PM

2 · Reply

skyrockets_Inc Mar. 19 at 2:14 PM

2 · Reply

StockTwitsGhost Mar. 18 at 9:43 PM

1 · Reply

Inlowouthigh Mar. 18 at 8:18 PM

$BIAF $CTMX $CYCN $INLF $NUAI your post is utterly ridiculous

0 · Reply

newyork1979 Mar. 18 at 7:03 PM

TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonals/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $CTMX $BIAF $CYCN $NUAI $INLF watch these

0 · Reply

StockTwitsGhost Mar. 17 at 10:30 PM

$CYCN Revised Ownership Analysis — SEC Filings (Form 3, 4, 13D, 13G, 13F) Total Shares Outstanding: 3.925M TOTAL KNOWN CONCENTRATED OWNERSHIP ~2,141,377 shares = 54.6% Notably, all private placement participants Peter Hecht, Michael Higgins, J. Wood Capital, Joe Cook, and Polaris/McGuire purchased their shares in the March 2025 placement at $2.75/share, below current trading prices, and none have filed amended disclosures indicating any sales. INSIDERS (35.8%) Peter Hecht — 1,028,086 (26.2%) [incl. preferred + options] Regina Graul CEO — 100,303 (2.56%) [RSUs + options] Joe C. Cook Jr. — 95,602 (2.44%) Errol DeSouza Chair — 80,000 (2.04%) [RSUs] Terrance McGuire — 77,373 (1.97%) [41,010 direct + 36,363 Polaris] Michael Higgins — 30,740 (0.78%) Steven Hyman — 20,000 (0.51%) [RSUs] Dina Katabi — 20,000 (0.51%) [RSUs] Rhonda Chicko CFO — 18 common + 25,000 options

3 · Reply

StockTwitsGhost Mar. 17 at 8:58 PM

$CYCN CYCN Ownership Analysis — SEC Filings (Form 3, 4, 13D, 13G, 13F) Total Shares Outstanding: 3.925M TOTAL KNOWN CONCENTRATED OWNERSHIP ~2,020,261 shares = 50.4% Float is razor thin. 👀 INSIDERS (33.6%) Peter Hecht — 1,028,086 (26.2%) [incl. preferred] Regina Graul CEO — 100,303 (2.56%) [incl. RSUs + options] Errol DeSouza Chair — 80,000 (2.04%) [RSUs] Terrance McGuire — 41,010 (1.04%) Michael Higgins — 30,740 (0.78%) Steven Hyman — 20,000 (0.51%) [RSUs] Dina Katabi — 20,000 (0.51%) [RSUs] Rhonda Chicko CFO — 18 + 25,000 options INSTITUTIONS (15.8%) J. Wood Capital (13G) — 181,818 (4.63%) Tyndall Capital (13G) — 155,187 (3.95%) Siren LLC/Invus (13F) — 115,603 (2.95%) Geode Capital (13F) — 43,302 (1.10%) Two Sigma (13F) — 69,855 (1.78%) Vanguard (13F) — 23,490 (0.60%)

2 · Reply

StockTwitsGhost Mar. 17 at 6:35 PM

$CYCN There is a narrative circulating suggesting that CYCN’s low volume prevents longs from exiting positions. It is important to clarify that CYCN is a micro-cap, low-float security, with over 50% of shares held by insiders. Anyone familiar with CYCN would recognize that the “low volume trap” thesis is fundamentally flawed. I strongly question the origin of this narrative, which appears to be driven more by retail short interest—and potentially market-maker activity—than by any structural liquidity constraint. For context, trading data from November 8 to December 6, 2024, shows volumes ranging from as low as 11,700 shares to as high as 141 million shares. Such episodic spikes in volume are not anomalous and have recurred multiple times, most recently as of January 2026. Those genuinely concerned about liquidity constraints clearly do not appreciate the trading dynamics of CYCN, which exhibits substantial volatility and episodic volume surges that belie the notion of a low volume trap

2 · Reply

skyrockets_Inc Mar. 17 at 5:06 PM

$CYCN Volume picking up and breaking above 100 and 50SMAs. Solid.

1 · Reply

OPTIONTURD Mar. 17 at 5:04 PM

$CYCN Some mf-er just sold off 15,000 shares....thanks a lot...:-( 1.56 down to 1.44

2 · Reply

skyrockets_Inc Mar. 17 at 3:05 PM

$CYCN About to start getting more expensive around here. Trying to add as much as possible while it's still at these levels.

0 · Reply

spinooch Mar. 17 at 2:49 PM

$CYCN what does a guy have to do to get some volume around here?

1 · Reply

AshleySchaeffer_BMW Mar. 17 at 2:28 PM

$CYCN shorts below...

0 · Reply

StockTwitsGhost Mar. 17 at 4:02 AM

$CYCN @skyrockets_Inc @skyhopes @Mr_Pithy @EZYME22 This is a sophisticated, filing-driven deep dive that highlights real, overlooked assets and near-term disclosure windows. The verifiable pieces (stake, pipeline progress, FDA/Akebia updates, 10-K delay) hold up strongly. The Series B revaluation thesis is the high-conviction “secret” that could drive explosive upside or fizzle if the MA signals are misinterpreted or the round terms disappoint. The $5 Million Company Hiding a $32 Million Secret in Plain Sight The completion of this analysis was timed to the Massachusetts annual filing deadline — and its passage today without a filing from either Cyclerion entity serves as unambiguous confirmation of the central thesis. Cyclerion’s Massachusetts annual filing delay is one of the most significant forward-looking signals in this story — and when read against the complete public record, it points to a conclusion that the market has entirely missed. https://x.com/GainOf1/status/2033751440607613343

1 · Reply

skyrockets_Inc Mar. 16 at 6:20 PM

$CYCN Playing with the numbers . Reverse merger scenario: -Cash + Shell value: ~10M -10% Tisento Stake Post Series B (risk-adjusted): ~25M -Praliciguat Akebia Deal (up to 450M milestones, risk-adjusted): ~20M -Olinciguat (not yet out-licensed): ~5M -Total RM value: ~60M -Shares outstanding: ~3.9M Total RM value per share: $15/share If Regina can pull off a successful reverse merger like above she will be a hero in my eyes :)

3 · Reply

Market Cap	5.73M
Revenue (ttm)	2.00M
Net Income (ttm)	-3.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.00%
Debt to Equity Ratio	0.00

Volume	61,600
Avg Vol	108,900
Day's Range	N/A - N/A
Shares Out	3.93M
Stochastic %K	91%
Beta	0.94
Analysts	Strong Buy
Price Target	$8.00